Bibliometric analysis of levosimendan.

Int J Cardiol Heart Vasc

Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Published: February 2025

Background: Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.

Methods: LEVO-related publications from 1990 to 2023 were searched and retrieved in the Web of Science Core Collection (WoSCC) and analyzed with VOSviewer, CiteSpace, Scimago Graphica, R-bibliometrix and Rstudio for publication dates, countries/regions, institutions, authors, keywords, journals, and references.

Results: Finally, a total of 1,432 LEVO-related articles were included in the present study. Annual LEVO-related publications have been increased yearly. The United States was the most productive country with 243 articles. The University of Helsinkin published 69 articles in the field of LEVO, which were the most productive institution among all the institutions. Of all the authors, professor Pollesello,Piero was the most productive author with 62 articles. Moreover, the results of the co-citation analysis and citation bursts analysis revealed that the safety and effectiveness of LEVO were the global research trends and potential hot spots.

Conclusions: This study systematically summarizes the current status in the field of LEVO and provides insights into the research focuses and future hotspots.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719333PMC
http://dx.doi.org/10.1016/j.ijcha.2024.101571DOI Listing

Publication Analysis

Top Keywords

levo-related publications
12
institutions authors
8
field levo
8
levo
5
bibliometric analysis
4
analysis levosimendan
4
levosimendan background
4
background levosimendan
4
levosimendan levo
4
levo calcium
4

Similar Publications

Bibliometric analysis of levosimendan.

Int J Cardiol Heart Vasc

February 2025

Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!